Erasca, Inc.
ERAS
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.6B
$16.19
▼ -0.43%
P/E
-17.04
Mkt Cap
$5.6B
52-Wk Range
$1.53–$24.28
52-Week Range
$1.53 - $24.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 944.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Focused pipeline targeting RAS/MAPK pathway with multiple mechanistic approaches
- Oral small-molecule formulations improving patient accessibility and compliance
- CNS-penetrant EGFR inhibitor addressing underserved glioblastoma market
- Experienced management team with deep oncology and RAS pathway expertise
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Clinical trial progression and potential regulatory approvals for lead candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+25.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ERAS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.14 vs -$0.11 consensus (-25.7% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-25.7%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 13, 2026
vs Industry
How ERAS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related